Immune Checkpoint Proteins, Metabolism and Adhesion Molecules: Overlooked Determinants of CAR T-Cell Migration?
Adoptive transfer of T cells genetically engineered to express chimeric antigen receptors (CAR) has demonstrated striking efficacy for the treatment of several hematological malignancies, including B-cell lymphoma, leukemia, and multiple myeloma. However, many patients still do not respond to this t...
Main Authors: | Luca Simula, Emma Ollivier, Philippe Icard, Emmanuel Donnadieu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/11/1854 |
Similar Items
-
Using the Power of Junctional Adhesion Molecules Combined with the Target of CAR-T to Inhibit Cancer Proliferation, Metastasis and Eradicate Tumors
by: Christopher Mendoza, et al.
Published: (2022-02-01) -
New insights into CAR T cell-mediated killing of tumor cells
by: David Espie, et al.
Published: (2022-09-01) -
Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
by: Jingjing Zhao, et al.
Published: (2023-12-01) -
EpCAM-targeting CAR-T cells against hepatoma cells in vitro
by: WANG Song, et al.
Published: (2023-09-01) -
Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy
by: Wenjiao Xia, et al.
Published: (2023-04-01)